3 Automotive Control Cables Maker, Business Process Services Company and Pharma Ingredients Maker Stocks With a Strong Future Roadmap: Suprajit Engineering, Firstsource Solutions and Divi's Laboratories

Control cable, BPO and drug ingredient stocks bring together companies with a visible plan for the years ahead. Suprajit Engineering, Firstsource Solutions and Divi's Laboratories cover an automotive control cables maker, a business process services company and a pharma ingredients maker.

This list covers three control cable, BPO and drug ingredient stocks with complete current figures: Suprajit Engineering, Firstsource Solutions and Divi's Laboratories. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Control Cable, BPO and Drug Ingredient Stocks?

Control cable, BPO and drug ingredient stocks are listed companies that make control cables and driver controls for vehicles, provide customer experience and business process services to global clients, and produce active pharmaceutical ingredients and intermediates. Their earnings depend on vehicle output, client outsourcing budgets and pharma sourcing.

Control Cable, BPO and Drug Ingredient Stocks at a Glance

On valuation, Suprajit Engineering trades at a P/E below the industry P/E, while Firstsource Solutions and Divi's Laboratories trade above it, which reflects the growth the market already expects. Readers comparing control cable, BPO and drug ingredient stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in control cable, BPO and drug ingredient stocks can use the coming numbers to test whether growth is holding.

Why Do Control Cable, BPO and Drug Ingredient Stocks Have a Strong Roadmap in India?

Control cable, BPO and drug ingredient stocks have a strong roadmap in India because rising vehicle production, wider outsourcing of customer services and steady global demand for generic drug inputs keep widening the market for these companies.

• Control cables. Every vehicle needs precise controls.
• Process services. Global firms outsource customer work.
• Pharma ingredients. Drug makers need dependable inputs.

Why Suprajit Engineering Features Among These Control Cable, BPO and Drug Ingredient Stocks

Among the control cable, BPO and drug ingredient stocks on this list, Suprajit Engineering is a Bengaluru-based maker of automotive cables and control systems, lighting products and other components for two-wheelers, cars and commercial vehicles, with a presence in many countries.

The company has a return on equity of 12.7%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 6,286 crore. The stock trades at a P/E of 33.6, below the industry P/E of 36.1.

Revenue rose from Rs 1,877 crore in FY22 to Rs 3,941 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 152 crore in FY23 to Rs 183 crore in FY26, which works out to a compound annual growth rate of 6.3%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,074 crore, while net profit rose 8.6% to Rs 52.2 crore.

Roadmap: The company is widening its mix through lighting, electronics and aftermarket products while keeping its strong cable franchise. A global footprint supports orders from international vehicle makers.

What to watch: Follow growth in new product lines, export programmes and margin trends.

Why Firstsource Solutions Features Among These Control Cable, BPO and Drug Ingredient Stocks

Among the vehicle cable, outsourcing and pharma input shares on this list, Firstsource Solutions, an RPG group company, is a business process management firm serving banks, healthcare payers and providers, and other clients, mainly in the United States and the United Kingdom.

Revenue rose from Rs 5,922 crore in FY22 to Rs 9,564 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 537 crore in FY22 to Rs 674 crore in FY26, which works out to a compound annual growth rate of 5.9%.

In the June 2026 quarter, revenue grew 22.8% year on year to Rs 2,731 crore. The company has a return on equity of 17.1%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 19,489 crore. The stock trades at a P/E of 29.1, above the industry P/E of 17.5.

Roadmap: It is growing in healthcare and mortgage services, pursuing larger deals and using artificial intelligence to improve productivity. Longer contracts with large clients give it visibility on revenue.

What to watch: Follow contract wins in healthcare and the pace of new technology investments.

Why Divi's Laboratories Features Among These Control Cable, BPO and Drug Ingredient Stocks

Among the three companies on this list, Divi's Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%.

Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Suprajit Engineering vs Firstsource Solutions vs Divi's Laboratories on Key Financials

The table below sets the three control cable, BPO and drug ingredient stocks side by side on revenue, profit and margin, using reported figures.

Firstsource Solutions posts the highest return on equity in this group at 17.1%. Divi's Laboratories has the largest FY26 revenue at Rs 11,067 crore, and Suprajit Engineering shows the fastest revenue growth with a 20.4% compound annual rate. A useful habit with control cable, BPO and drug ingredient stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Control Cable, BPO and Drug Ingredient Stocks

Every theme carries risks that deserve a check before any decision. For these control cable, BPO and drug ingredient stocks, the main points are: Long-term vehicle cable, outsourcing and pharma input shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Production cycles. Vehicle output can vary with demand.
• Client concentration. A few large clients contribute a big share of revenue.
• Regulatory approvals. Plant inspections and approvals can affect supplies.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter control cable, BPO and drug ingredient stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Control Cable, BPO and Drug Ingredient Stocks

Control cable, BPO and drug ingredient stocks suit investors who prefer to study business strength before price moves. Suprajit Engineering, Firstsource Solutions and Divi's Laboratories each have a clear plan to grow. Based on the 11 November 2026 close, Suprajit Engineering trades at Rs 463.85, Firstsource Solutions at Rs 295.25 and Divi's Laboratories at Rs 11,367. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these control cable, BPO and drug ingredient stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track control cable, BPO and drug ingredient stocks, set price alerts and get research-backed stock ideas.

What are control cable, BPO and drug ingredient stocks?

Ans. Control cable, BPO and drug ingredient stocks are listed companies that make control cables and driver controls for vehicles, provide customer experience and business process services to global clients, and produce active pharmaceutical ingredients and intermediates. Their earnings depend on vehicle output, client outsourcing budgets and pharma sourcing. This list looks at three of them, Suprajit Engineering, Firstsource Solutions and Divi's Laboratories, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which control cable, BPO and drug ingredient stocks are covered in this list?

Ans. This list covers Suprajit Engineering, Firstsource Solutions and Divi's Laboratories. Based on the 11 November 2026 close, Suprajit Engineering traded at Rs 463.85, Firstsource Solutions at Rs 295.25 and Divi's Laboratories at Rs 11,367. Their return on equity ranges from 12.7% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 20.4%.

Why do control cable, BPO and drug ingredient stocks have a strong future roadmap in India?

Ans. Control cable, BPO and drug ingredient stocks have a strong roadmap in India because rising vehicle production, wider outsourcing of customer services and steady global demand for generic drug inputs keep widening the market for these companies. The main drivers are as follows. Control cables. Every vehicle needs precise controls. Process services. Global firms outsource customer work. Pharma ingredients. Drug makers need dependable inputs. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Suprajit Engineering performed financially?

Ans. Revenue rose from Rs 1,877 crore in FY22 to Rs 3,941 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 152 crore in FY23 to Rs 183 crore in FY26, which works out to a compound annual growth rate of 6.3%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,074 crore, while net profit rose 8.6% to Rs 52.2 crore. The company has a return on equity of 12.7%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 6,286 crore. The stock trades at a P/E of 33.6, below the industry P/E of 36.1. Looking ahead, the company is widening its mix through lighting, electronics and aftermarket products while keeping its strong cable franchise. A global footprint supports orders from international vehicle makers.

How has Firstsource Solutions performed financially?

Ans. Revenue rose from Rs 5,922 crore in FY22 to Rs 9,564 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 537 crore in FY22 to Rs 674 crore in FY26, which works out to a compound annual growth rate of 5.9%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 2,731 crore. The company has a return on equity of 17.1%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 19,489 crore. The stock trades at a P/E of 29.1, above the industry P/E of 17.5. Looking ahead, it is growing in healthcare and mortgage services, pursuing larger deals and using artificial intelligence to improve productivity. Longer contracts with large clients give it visibility on revenue.

How has Divi's Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What risks should investors check before buying control cable, BPO and drug ingredient stocks?

Ans. Investors should check a few risks before buying control cable, BPO and drug ingredient stocks. Production cycles. Vehicle output can vary with demand. Client concentration. A few large clients contribute a big share of revenue. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of control cable, BPO and drug ingredient stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.